Mattern Capital Management LLC Has $8.37 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Mattern Capital Management LLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 1.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,252 shares of the company’s stock after purchasing an additional 479 shares during the period. Mattern Capital Management LLC’s holdings in Zoetis were worth $8,365,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Webster Bank N. A. increased its stake in shares of Zoetis by 89.1% in the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares during the period. Private Wealth Management Group LLC acquired a new stake in Zoetis during the 4th quarter valued at approximately $33,000. Gladius Capital Management LP bought a new position in Zoetis during the 4th quarter worth approximately $40,000. Neo Ivy Capital Management acquired a new position in shares of Zoetis in the 4th quarter worth approximately $40,000. Finally, LRI Investments LLC bought a new stake in shares of Zoetis in the 1st quarter valued at $43,000. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Up 2.0 %

ZTS opened at $187.33 on Thursday. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company’s 50-day moving average is $180.70 and its 200 day moving average is $174.48. The firm has a market capitalization of $85.48 billion, a P/E ratio of 36.09, a PEG ratio of 2.81 and a beta of 0.88. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.45 and a quick ratio of 2.09.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same period last year, the business posted $1.41 earnings per share. Zoetis’s revenue was up 8.3% on a year-over-year basis. Research analysts expect that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on ZTS. Argus raised Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. BTIG Research increased their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Piper Sandler lifted their price target on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Stifel Nicolaus restated a “buy” rating and set a $200.00 price objective on shares of Zoetis in a report on Tuesday, August 27th. Finally, HSBC decreased their target price on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Nine equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of “Buy” and a consensus price target of $217.11.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.